Growing Product Portfolio Immunodiagnostic Systems continuously expands its range of immunoassays and automated analyzers, including new assays like the IDS Cortisol and SARS-CoV-2 IgG tests, presenting opportunities to upsell and cross-sell advanced diagnostic solutions to existing clients.

Strategic Industry Acquisition The acquisition by PerkinElmer in 2021 positions IDS within a broader diagnostics ecosystem, enabling cross-promotional opportunities with a global leader and potential access to larger institutional clients seeking integrated diagnostic solutions.

Market Expansion Potential IDS's integration within Euroimmun facilitates access to international markets and diverse healthcare systems, allowing sales teams to target regions where demand for in vitro diagnostics is rapidly increasing, especially in response to COVID-19 and endocrine testing needs.

Partnership and Collaboration Collaborations with partners like Technogenetics highlight opportunities to co-develop and co-market innovative tests, opening doors for joint sales efforts in expanding the portfolio of automated and high-throughput diagnostic assays.

Customer Focused Innovation By launching multiple new assays on advanced automated platforms, IDS demonstrates a commitment to meeting evolving clinical laboratory demands, creating opportunities to position their solutions as essential for labs investing in high efficiency and rapid diagnostic capabilities.